We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability.
- Authors
Anderson, Michael S.; Nadkarni, Anish; Cardwell, Leah A.; Alinia, Hossein; Feldman, Steven R.
- Abstract
Background: Brimonidine tartrate is a highly selective alpha 2 agonist that induces direct vasoconstriction of small arteries and veins, thereby reducing vasodilation and edema. Objective: To review the current literature regarding the safety, efficacy, and patient acceptability of brimonidine 0.33% gel. Methods: A PubMed search was performed using the terms brimonidine 0.33% gel, rosacea, safety, efficacy, and acceptability. Peer-reviewed clinical trials and case reports from 2012 to 2016 were screened for inclusion of safety, efficacy, and/or patient acceptability data. Results: Brimonidine topical gel 0.33% is associated with mild, transient skin-related adverse reactions. Efficacy may be achieved within 30 minutes of administration with maximal reductions in erythema 3-6 hours after administration. Patient satisfaction with use of brimonidine topical gel is superior to vehicle gel for facial appearance, treatment effect, facial redness, and daily control of facial redness. Limitations: Studies were typically limited to 1-year follow-up. Only one study has examined the use of brimonidine topical gel in combination with other rosacea and acne medications. Discussion: Brimonidine topical gel 0.33% is a safe, effective, and patient-accepted treatment for facial erythema of rosacea.
- Subjects
ERYTHEMA; ROSACEA; PATIENT safety; VASODILATION; EDEMA
- Publication
Patient Preference & Adherence, 2017, Vol 11, p1143
- ISSN
1177-889X
- Publication type
Article
- DOI
10.2147/PPA.S115708